# GCC DNA Synthesis Market

> GCC DNA Synthesis Market Research Report By Application (Gene Therapy, Synthetic Biology, Molecular Diagnostics, Vaccine Development), By Product Type (Oligonucleotides, Gene Fragments, Gene Libraries), By End User (Academic Research Institutions, Pharmaceutical Companies, Biotechnology Companies, Clinical Laboratories) and By Technology (Solid-Phase Synthesis, Liquid-Phase Synthesis, PCR-Based Synthesis) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.05%
- **2024:** $ 72.54 Million
- **2025:** $ 85.64 Million
- **2035:** $ 450 Million
- **Key Players:** Thermo Fisher Scientific (US), Illumina (US), Integrated DNA Technologies (US), Eurofins Genomics (DE), GenScript (CN), Twist Bioscience (US), Synthetic Genomics (US), Bioneer (KR), DNA Script (FR)

**Report ID:** MRFR/HC/50500-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/gcc-dna-synthesis-market-52258

---

## Market Summary

## **GCC DNA Synthesis Market Overview**

As per MRFR analysis, the GCC DNA Synthesis Market Size was estimated at 106 (USD Million) in 2023. The GCC DNA Synthesis Market Industry is expected to grow from 115.75(USD Million) in 2024 to 290 (USD Million) by 2035. The GCC DNA Synthesis Market CAGR (growth rate) is expected to be around 8.708% during the forecast period (2025 - 2035)

**Key GCC DNA Synthesis Market Trends Highlighted**

The GCC DNA Synthesis Market is experiencing significant growth due to various key market drivers. The region's increasing investment in biotechnology and life sciences by governments and private sectors has led to the enhancement of research capabilities. Initiatives to promote genomic research are also being supported by government policies aimed at diversifying economies beyond oil dependency. This is evident in countries like the UAE and Saudi Arabia, where national strategies emphasize biotechnology's role in health and agriculture. 

Opportunities to be explored in the GCC include the rising demand for personalized medicine and synthetic biology applications.The population's growing awareness of genetic testing and its implications for healthcare is driving the need for advanced DNA synthesis technologies. Additionally, collaborations between academic institutions and industry players are fostering innovation in the market. The establishment of biobanks and research centers across the GCC is helping to advance local capabilities, creating a favorable environment for DNA synthesis services. 

Recent trends in the GCC show an increase in the adoption of cloud-based DNA synthesis platforms, allowing researchers easier access to data and services. Furthermore, the growing focus on sustainable practices in biotechnology is pushing for more eco-friendly synthesis methods.Technological advancements, such as CRISPR and next-generation sequencing, are also influencing the landscape of DNA synthesis, making it more accurate and efficient. 

Overall, the GCC DNA Synthesis Market is marked by a dynamic interplay of government support, innovative research initiatives, and a shift towards modern technologies that enhance the region's biotechnology ecosystem.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**GCC DNA Synthesis Market Drivers**

**Increase in Research and Development Activities**

The growing emphasis on research and development (R&D) activities in the biotechnology and pharmaceutical industries is driving the GCC DNA Synthesis Market Industry's notable expansion. Gulf Cooperation Council nations like Saudi Arabia and the United Arab Emirates are investing more in research and development. This is demonstrated by Saudi Arabia's national transformation program, which aims to invest more than USD 120 billion in innovative areas by 2030. 

As a result of this financial rise, genetic research and biotechnology have advanced, increasing demand for DNA synthesis services and goods. Establishments that are setting the standard by improving research infrastructure and promoting cooperation include the Dubai Science Park and King Abdulaziz City for Science and Technology. Therefore, as these developments drive the use of DNA synthesis in a variety of domains, such as environmental research, agriculture, and medicine, the GCC DNA Synthesis Market Industry is anticipated to see strong expansion.

**Growing Prevalence of Genetic Disorders**

The rising prevalence of genetic disorders is a significant driver for the GCC DNA Synthesis Market Industry. Reports indicate that genetic disorders affect approximately 1 in 88 live births in the Gulf region, reflecting an alarming trend. Governments in the GCC are focusing on establishing genetic screening programs to combat this rise, as highlighted by the UAE's initiative to implement newborn screening for genetic diseases by 2025. 

This government-backed focus on public health drives the demand for DNA synthesis technologies, which are essential in the development of diagnostic tools and treatment options, including gene therapy.Organizations such as the Emirati Genome Program aim to identify genetic markers of various diseases, reinforcing the need for advanced DNA synthesis capabilities within the region.

**Expansion of Biotechnology and Pharmaceutical Industries**

The GCC DNA Synthesis Market Industry is benefiting from the rapid expansion of the biotechnology and pharmaceutical industries within the region. The GCC has been making strides in developing local medicine and biopharmaceutical production capabilities as part of long-term economic diversification plans. For instance, the UAE’s biopharmaceutical sector is expected to have a compound annual growth rate of around 12% over the next five years, driven by an increase in local production and research collaborations with global pharmaceutical giants.

This expansion further enhances the demand for DNA synthesis, as it plays a critical role in drug development, personalized medicine, and immunotherapies. Moreover, initiatives from established pharmaceutical companies are actively contributing to growth in the GCC DNA Synthesis Market Industry, leading to increased investments in biotechnological innovations.

**GCC DNA Synthesis Market Segment Insights**

**DNA Synthesis Market Application Insights**

The Application segment of the GCC DNA Synthesis Market plays a crucial role in driving innovation and advancements within the biotechnology and life sciences industry across the region. The significance of Gene Therapy is becoming increasingly evident as it provides potential solutions for a variety of genetic disorders, leading to the development of targeted therapies that focus on correcting genetic abnormalities. This focus aligns with the GCC's growing investments in healthcare technologies, particularly within the Gulf Cooperation Council states, where government initiatives emphasize improving public health outcomes. 

In the realm of Synthetic Biology, companies within the GCC are leveraging DNA synthesis for designing and constructing new biological parts, devices, and systems. This application is vital for addressing complex challenges in areas such as environmental sustainability and renewable energy, which are priorities within the strategic frameworks of GCC nations striving for diversification beyond oil dependency. Molecular Diagnostics is also a pivotal area under this segment, offering crucial tests that enhance disease detection and patient management.

The GCC's increasing focus on personalized medicine and advanced diagnostic techniques reflects a wider shift towards improving healthcare infrastructure and accessibility in the region. 

The advancements in molecular diagnostics are predominantly driven by the rising prevalence of chronic diseases, necessitating advanced solutions for timely diagnosis and treatment. Vaccine Development remains a key driver within the Application segment, especially highlighted by the global response to health crises like the COVID-19 pandemic. The GCC is prioritizing vaccine research and development through collaborative efforts with international organizations and local institutions, reinforcing their commitment to public health and safety. The rapid growth and exploration of vaccine technology in the region emphasize the potential for increased resilience against infectious diseases and contribute to the overall healthcare landscape.

As the GCC nations invest heavily in biotechnology and supportive infrastructure, the Application segment of the DNA Synthesis Market continues to evolve and expand dynamically. Each application derives insights from cutting-edge research, indicating a holistic approach to healthcare and life sciences within the region, ensuring that the GCC remains at the forefront of innovation and technological advancement in the DNA synthesis domain.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**DNA Synthesis Market Product Type Insights**

The GCC DNA Synthesis Market demonstrates a diverse range of Product Types, with key components including Oligonucleotides, Gene Fragments, and Gene Libraries. Oligonucleotides are vital in numerous applications such as diagnostics and therapeutic development, contributing significantly to market dynamics due to their versatility and applicability in Research and Development fields. Gene Fragments are increasingly gaining traction as they facilitate the creation of recombinant DNA and synthetic biology projects, driving market demand as biotechnology continues to evolve.

Meanwhile, Gene Libraries, which enable comprehensive genomic analysis and functional genomics, play a crucial role in the advancement of personalized medicine and agricultural improvements. As the GCC region invests heavily in biotechnology infrastructure and Research and Development initiatives, these product types are poised to influence market growth and evolution significantly, addressing challenges like genetic disorders and food security while offering abundant opportunities for innovation. The strong presence of emerging biotechnologies in the GCC is also boosting interest in these Product Types, aligning with national strategies aimed at fostering a knowledge-based economy.

**DNA Synthesis Market End User Insights**

The End User segment within the GCC DNA Synthesis Market boasts a diverse landscape comprised of Academic Research Institutions, Pharmaceutical Companies, Biotechnology Companies, and Clinical Laboratories. Academic Research Institutions play a pivotal role in advancing genomic research and innovation, often serving as the foundation for breakthroughs in DNA synthesis methodologies. In contrast, Pharmaceutical Companies are crucial as they leverage DNA synthesis technologies for drug development and therapeutic advancements, helping to streamline research processes.Biotechnology Companies significantly contribute to the development of synthetic biology applications, enabling the generation of novel products and solutions that address healthcare challenges. 

Clinical Laboratories utilize DNA synthesis for diagnostic purposes, making it vital for personalized medicine approaches and patient management. Overall, the importance of these End User segments cannot be overstated, as they drive not only growth but also foster significant advancements in the biotechnology and healthcare sectors within the GCC region, aligning with the increasing focus on research and innovation among Gulf Cooperation Council countries.This dynamic interplay among diverse sectors underscores the vital role these entities play in the overall GCC DNA Synthesis Market framework.

**DNA Synthesis Market Technology Insights**

The Technology segment of the GCC DNA Synthesis Market plays a crucial role in the overall market dynamics and growth trajectory. Solid-Phase Synthesis is favored for its efficiency in producing high-quality DNA sequences, while Liquid-Phase Synthesis offers flexibility and versatility for various applications, making both techniques essential in meeting the rising demand from fields such as biotechnology and pharmaceuticals. 

Additionally, PCR-Based Synthesis serves as a foundational technique due to its effectiveness in amplifying DNA, significantly empowering Research and Development initiatives in genetic research and diagnostics.The GCC region's commitment to advancing its biotechnology sectors and fostering innovation reflects the increasing adoption of these technologies, which are vital for meeting healthcare demands and addressing genetic disorders. 

Market growth also signifies strong investment in education and infrastructure, further driving advancements in DNA synthesis technologies. The segment continues to evolve, supported by ongoing trends such as personalized medicine and genomics, which fuel the need for efficient and reliable DNA synthesis solutions. As the GCC strives to establish itself as a hub for biotech and genetic research, these technology-driven methods are fundamental in advancing the capabilities and applications of DNA synthesis across various industries.

**GCC DNA Synthesis Market Key Players and Competitive Insights**

The GCC DNA Synthesis Market has been experiencing significant growth driven by advancements in biotechnology and pharmaceuticals, leading to increased adoption of synthetic DNA for various applications, including genomics, molecular diagnostics, and drug discovery. The competitive landscape is characterized by the presence of several key players who are focusing on innovation and expanding their product offerings to meet the rising demand for customized DNA synthesis services. 

Companies are investing in research and development to enhance their technical capabilities and improve service efficiency, ultimately aiming to capture a larger market share in the region. As healthcare systems and research institutions in the GCC continue to evolve, the competition among these entities is likely to intensify, fostering an environment conducive to continuous progression and technological advancements.Agilent Technologies stands out in the GCC DNA Synthesis Market with its comprehensive portfolio of solutions, which includes high-quality DNA synthesis services and advanced sequencing technologies.

The company leverages its expertise in analytical instrumentation to deliver reliable and cost-effective products that cater to researchers and clinical laboratories across the region. 

The strength of Agilent Technologies lies in its ability to provide tailored solutions that meet specific customer needs, along with a strong focus on innovation, ensuring that its offerings remain at the forefront of the industry. Moreover, Agilent's established relationships with local institutions and collaboration with various research initiatives have reinforced its market presence, allowing the company to maintain a competitive edge in the rapidly evolving GCC landscape.Eurofins Genomics is another prominent player in the GCC DNA Synthesis Market, renowned for its robust suite of genomic services that includes DNA synthesis, sequencing, and oligonucleotide production. 

The company's commitment to quality and reliability has positioned it as a preferred partner for biotech firms and academic institutions in the region. With a strong emphasis on customer service, Eurofins Genomics continually invests in state-of-the-art technology and quality assurance processes, enhancing its product offerings. Recent mergers and acquisitions have further strengthened its capabilities, allowing for increased scalability and an expanded service portfolio specifically tailored for GCC clients.

Eurofins Genomics’ ability to deliver rapid turnaround times and maintain competitive pricing has established it as a vital player in the GCC DNA synthesis landscape, catering to the growing demand for high-quality genomic solutions.

**Key Companies in the GCC DNA Synthesis Market Include**

**GCC DNA Synthesis Market Industry Developments**

The GCC DNA Synthesis Market has seen notable advancements recently, driven by increased investments and technological innovations. Companies like Agilent Technologies, Thermo Fisher Scientific, and Qiagen are expanding their operations in the region, enhancing capabilities for genetic research and biopharmaceutical applications. In September 2023, Eurofins Genomics increased its production capacity in the UAE to cater to rising demands, highlighting market growth and expansion. In 2022, Integrated DNA Technologies launched a new service center in Saudi Arabia, facilitating local access to synthetic DNA products. 

Merger and acquisition activities have also shaped the landscape; for instance, in June 2023, Thermo Fisher Scientific acquired a biomanufacturing facility in Bahrain, strengthening its supply chain in the GCC. Additionally, the market has been positively impacted by increased governmental support for biotechnology research as outlined in the UAE National Innovation Strategy. This support is expected to provide a significant boost for companies like Bioneer and SciGene, enhancing their market presence. The collective efforts of key players and supportive policies are expected to drive further advancements in the GCC DNA Synthesis Market in the coming years.

**GCC DNA Synthesis Market Segmentation Insights**

## Market Drivers

### Collaborations and Partnerships

Collaborations between academic institutions, research organizations, and private companies are becoming increasingly prevalent in the GCC, significantly influencing the DNA Synthesis Market. These partnerships are often aimed at advancing research in synthetic biology and genetic engineering, leading to the development of innovative products and services. For instance, joint ventures between universities and biotech firms are facilitating the sharing of knowledge and resources, which is essential for driving advancements in dna synthesis technologies. Such collaborations may also attract foreign investment, further enhancing the capabilities of the local dna synthesis market. As these partnerships continue to grow, they are likely to foster a more dynamic and competitive environment, ultimately benefiting the entire industry.

### Expansion of Research Institutions

The establishment and expansion of research institutions in the GCC are significantly impacting the DNA Synthesis Market. Universities and research centers are increasingly focusing on genetic research and synthetic biology, leading to a higher demand for dna synthesis services. For example, several universities in the region have launched dedicated programs in biotechnology and molecular biology, which are expected to produce a skilled workforce adept in dna synthesis techniques. This academic focus is likely to stimulate collaboration with industry players, thereby enhancing the overall capabilities of the dna synthesis market. Furthermore, government initiatives aimed at promoting research and innovation are expected to bolster funding for these institutions, facilitating further advancements in dna synthesis technologies.

### Growing Applications in Healthcare

The healthcare sector in the GCC is witnessing a growing reliance on dna synthesis technologies for various applications, including personalized medicine, diagnostics, and therapeutics. The increasing prevalence of genetic disorders and chronic diseases is driving demand for tailored treatment solutions, which often require custom dna synthesis. The market for personalized medicine is expected to grow at a CAGR of over 15% in the coming years, indicating a robust opportunity for the DNA Synthesis Market. Additionally, advancements in gene editing technologies, such as CRISPR, are further propelling the need for precise dna synthesis, as these tools require high-quality synthetic dna for effective application in clinical settings.

### Rising Investment in Biotechnology

The DNA Synthesis Market in the GCC is experiencing a surge in investment, particularly from both public and private sectors. Governments are increasingly recognizing the potential of biotechnology to drive economic growth and improve healthcare outcomes. For instance, the GCC countries have allocated substantial budgets towards research and development in biotechnology, which is projected to reach approximately $1.5 billion by 2026. This influx of capital is likely to enhance the capabilities of local firms in the dna synthesis market, enabling them to innovate and expand their product offerings. Furthermore, the establishment of biotechnology parks and incubators in the region is fostering collaboration between academia and industry, thereby accelerating advancements in dna synthesis technologies.

### Increased Focus on Agricultural Biotechnology

Agricultural biotechnology is emerging as a key driver for the DNA Synthesis Market in the GCC. With the region facing challenges related to food security and sustainable agriculture, there is a growing interest in developing genetically modified crops that can withstand harsh environmental conditions. The dna synthesis market is poised to benefit from this trend, as the creation of genetically engineered plants often requires sophisticated dna synthesis techniques. The GCC countries are investing in research to develop crops that are drought-resistant and pest-resistant, which could potentially enhance agricultural productivity by up to 30%. This focus on agricultural innovation is likely to create new opportunities for companies operating within the dna synthesis market.

## Future Outlook

The [DNA synthesis Market](https://www.marketresearchfuture.com/reports/dna-synthesis-market-20306) is projected to grow at an 18.05% CAGR from 2025 to 2035, driven by advancements in biotechnology, increased demand for personalized medicine, and rising investments in genomics.

**New opportunities:**

- Development of customized DNA synthesis platforms for niche applications.
- Expansion of partnerships with biotech firms for co-development projects.
- Implementation of AI-driven analytics for optimizing synthesis processes.

By 2035, the DNA synthesis market is expected to achieve substantial growth, driven by innovation and strategic collaborations.

## Segment Insights

### By Application: Gene Therapy (Largest) vs. Vaccine Development (Fastest-Growing)

The GCC DNA Synthesis Market is exhibiting a varied distribution among its key application segments. Gene Therapy is currently the largest segment, capturing significant market share as it continues to gain traction in the region. Following closely, Molecular Diagnostics serves as a crucial aspect of the market, while Synthetic Biology is establishing its presence. Vaccine Development, a relatively newer application, is also growing rapidly, showcasing its importance in health responses.

Growth trends indicate a dynamic landscape in the GCC dna synthesis market, propelled by increasing investments in biotechnology and healthcare R&D. The rise in chronic diseases and the need for advanced medical treatments drive the adoption of Gene Therapy and Vaccines. Additionally, legislative support and technological advancements are fostering innovation in Synthetic Biology and Molecular Diagnostics, contributing to their upward growth trajectory.

Gene Therapy (Dominant) vs. Vaccine Development (Emerging)

Gene Therapy remains the dominant application within the GCC dna synthesis market, recognized for its transformative potential in treating genetic disorders by repairing or replacing faulty genes. This segment is characterized by robust investment and research initiatives, bolstered by successful clinical trials that enhance its credibility and acceptance. In contrast, Vaccine Development is emerging rapidly, recognized for its agility in addressing public health challenges, especially due to recent global health outbreaks. Its focus on rapid formulation and scalability positions it as an increasingly vital component of the market, appealing to stakeholders seeking innovative solutions to health emergencies.

### By Product Type: Oligonucleotides (Largest) vs. Gene Fragments (Fastest-Growing)

In the GCC DNA Synthesis Market, Oligonucleotides currently hold the largest market share among the product types, driven by their extensive use in various applications such as diagnostics and therapeutics. Gene Fragments and Gene Libraries also contribute to the market, but they occupy smaller segments relative to Oligonucleotides. This distribution reflects the established demand for oligonucleotides and their pivotal role in research and development within the region.

Looking ahead, the market exhibits promising growth trends, particularly for Gene Fragments, which are anticipated to be the fastest-growing segment. The rise in personalized medicine and gene therapies is propelling this growth, as researchers and biotech firms increasingly rely on gene fragments for innovative solutions. Additionally, advancements in synthesis technology and increasing investments in genomics are expected to further enhance the market landscape.

Oligonucleotides (Dominant) vs. Gene Fragments (Emerging)

Oligonucleotides represent the dominant force in the GCC dna synthesis market, characterized by their versatility and essential role in molecular biology, diagnostics, and therapeutic applications. Their established usage has positioned them as a vital component in various research projects and clinical applications. On the other hand, Gene Fragments are emerging as a key player, gaining traction due to the growing focus on genetic research and applications in synthetic biology. With their ability to offer targeted solutions in gene editing and synthesis, Gene Fragments are quickly capturing the interest of researchers and biotechnology companies, paving the way for significant growth and innovation in the coming years.

### By End User: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

The market share distribution within the end user segment of the GCC DNA Synthesis Market highlights that pharmaceutical companies constitute the largest portion, taking a significant lead due to their extensive research and development capabilities. In contrast, biotechnology companies are emerging as critical players, rapidly gaining market share with innovative applications of dna synthesis technologies in various biological research and development areas.

Growth trends in this segment demonstrate that while pharmaceutical companies continue to invest heavily in dna synthesis for drug discovery and development, biotechnology companies are witnessing a surge in demand driven by their ability to develop personalized medicine and targeted therapies. This shift is further fueled by advancements in technology and increased investments in research, which are enabling biotechnology firms to optimize their dna synthesis processes and expand their product offerings.

Academic Research Institutions (Dominant) vs. Clinical Laboratories (Emerging)

Academic research institutions are a dominant force in the GCC dna synthesis market, driven by their pivotal role in advancing scientific knowledge and facilitating breakthroughs in genetic research. These institutions possess substantial resources and collaboration networks, enabling them to effectively utilize dna synthesis for various research applications. On the other hand, clinical laboratories represent an emerging segment, leveraging dna synthesis to enhance diagnostic capabilities and personalized medicine solutions. As the healthcare landscape evolves, clinical laboratories are increasingly adopting these technologies to provide accurate and rapid testing, thus contributing to their growth in the market. The interplay between these segments is crucial, with academic institutions often advancing foundational research that informs clinical practices.

### By Technology: Solid-Phase Synthesis (Largest) vs. PCR-Based Synthesis (Fastest-Growing)

In the GCC DNA Synthesis Market, Solid-Phase Synthesis holds the largest market share among the various technologies. This method is widely adopted across numerous applications due to its efficiency and reliability in producing high-purity oligonucleotides. Liquid-Phase Synthesis, while utilized, holds a smaller share, primarily serving niche applications, whereas PCR-Based Synthesis is rapidly gaining traction with the increasing demand for rapid and scalable DNA amplification solutions.

The growth trends within this segment are heavily influenced by advancements in biotechnology and an increasing focus on personalized medicine. Solid-Phase Synthesis remains a staple due to its established processes, while PCR-Based Synthesis is positioned as a rising star, driven by innovation and a surge in healthcare applications requiring rapid testing and analysis capabilities. As research and development continue to evolve, these technologies are expected to adapt accordingly to meet market demands.

Technology: Solid-Phase Synthesis (Dominant) vs. PCR-Based Synthesis (Emerging)

Solid-Phase Synthesis is recognized as the dominant technology in the GCC dna synthesis market due to its robustness and ability to produce high-quality products. It has a well-established presence, serving various sectors including genomics and therapeutic developments. The method’s capability to streamline the synthesis process makes it a preferred choice among researchers and industries. On the other hand, PCR-Based Synthesis is emerging as a critical player, fueled by its rapid amplification properties and versatility in applications ranging from clinical diagnostics to genetic research. The ongoing development of PCR technologies indicates a promising future, where its efficiency can meet the growing demands of the biotechnology landscape, particularly in diagnostics and personalized medicine.

## Competitive Benchmarking

The dna synthesis market is currently characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for synthetic biology applications. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Twist Bioscience (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, while Illumina (US) emphasizes its leadership in sequencing technologies, which complements its dna synthesis capabilities. Twist Bioscience (US) is strategically positioned with its unique silicon-based synthesis platform, which allows for high-throughput and cost-effective solutions, thereby shaping the competitive environment through technological differentiation.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies like Integrated DNA Technologies (US) and GenScript (CN) is notable. These firms are enhancing their operational efficiencies and expanding their geographic reach, which contributes to a more competitive structure.

In October  Thermo Fisher Scientific (US) announced a strategic partnership with a leading research institution to develop next-generation sequencing technologies. This collaboration is expected to enhance their product offerings and solidify their position in the market by integrating cutting-edge research into their dna synthesis solutions. The partnership underscores the importance of innovation in maintaining competitive advantage.

In September  Illumina (US) launched a new line of synthesis reagents aimed at improving the accuracy and efficiency of dna synthesis processes. This product introduction is significant as it not only enhances their existing portfolio but also positions Illumina as a key player in the rapidly evolving landscape of synthetic biology, where precision is paramount.

In August  Twist Bioscience (US) expanded its manufacturing capabilities by opening a new facility dedicated to high-throughput dna synthesis. This strategic move is likely to increase their production capacity and meet the growing demand for synthetic genes, thereby reinforcing their competitive edge in the market. The expansion reflects a broader trend towards scaling operations to accommodate increasing market needs.

As of November  current competitive trends in the dna synthesis market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into production processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine market dynamics, as companies strive to offer unique solutions that meet the complex demands of the biotechnology sector.

## Recent News & Developments

The GCC DNA Synthesis Market has seen notable advancements recently, driven by increased investments and technological innovations. Companies like Agilent Technologies, Thermo Fisher Scientific, and Qiagen are expanding their operations in the region, enhancing capabilities for genetic research and biopharmaceutical applications. In September 2023, Eurofins Genomics increased its production capacity in the UAE to cater to rising demands, highlighting market growth and expansion. In 2022, Integrated DNA Technologies launched a new service center in Saudi Arabia, facilitating local access to synthetic DNA products. 

Merger and acquisition activities have also shaped the landscape; for instance, in June 2023, Thermo Fisher Scientific acquired a biomanufacturing facility in Bahrain, strengthening its supply chain in the GCC. Additionally, the market has been positively impacted by increased governmental support for biotechnology research as outlined in the UAE National Innovation Strategy. This support is expected to provide a significant boost for companies like Bioneer and SciGene, enhancing their market presence. The collective efforts of key players and supportive policies are expected to drive further advancements in the GCC DNA Synthesis Market in the coming years.

## Report Scope

| MARKET SIZE 2024 | 72.54(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 85.64(USD Million) |
| MARKET SIZE 2035 | 450.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.05% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Illumina (US), Integrated DNA Technologies (US), Eurofins Genomics (DE), GenScript (CN), Twist Bioscience (US), Synthetic Genomics (US), Bioneer (KR), DNA Script (FR) |
| Segments Covered | Application, Product Type, End User, Technology |
| Key Market Opportunities | Advancements in personalized medicine drive demand for tailored solutions in the dna synthesis market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the DNA synthesis market. |
| Countries Covered | GCC |

## Frequently Asked Questions

**Q: What is the current valuation of the GCC DNA synthesis market?**
A: The market valuation was $72.54 Million in 2024.

**Q: What is the projected market size for the GCC DNA synthesis market by 2035?**
A: The market is projected to reach $450.0 Million by 2035.

**Q: What is the expected CAGR for the GCC DNA synthesis market during the forecast period 2025 - 2035?**
A: The expected CAGR is 18.05% during the forecast period.

**Q: Which application segment had the highest valuation in 2024?**
A: Molecular Diagnostics had the highest valuation at $150.0 Million in 2024.

**Q: What are the key players in the GCC DNA synthesis market?**
A: Key players include Thermo Fisher Scientific, Illumina, Integrated DNA Technologies, and others.

**Q: Which product type segment is projected to grow significantly by 2035?**
A: Gene Libraries, valued at $180.0 Million in 2024, is projected to grow significantly.

**Q: What end-user segment contributed the most to the market in 2024?**
A: Biotechnology Companies contributed the most, with a valuation of $150.0 Million in 2024.

**Q: What technology segment is expected to dominate the market by 2035?**
A: PCR-Based Synthesis, valued at $180.0 Million in 2024, is expected to dominate.

**Q: How does the market valuation in 2024 compare to the projected valuation in 2035?**
A: The market valuation is expected to increase from $72.54 Million in 2024 to $450.0 Million in 2035.

**Q: What factors are driving growth in the GCC DNA synthesis market?**
A: Growth is driven by advancements in gene therapy, synthetic biology, and molecular diagnostics.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-dna-synthesis-market-52258*